A Randomized, Open-Label, Crossover Study to Evaluate the PK, Bioavailability, Dose Proportionality, Safety, and Tolerability of Single Doses of STS101, DHE Mesylate IM Injection and DHE Mesylate Nasal Spray in Healthy Adult Subjects
Latest Information Update: 05 Aug 2022
At a glance
- Drugs Dihydroergotamine mesilate (Primary) ; Dihydroergotamine mesilate (Primary)
- Indications Migraine
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Satsuma Pharmaceuticals
- 12 Jun 2022 Results presented at the 64th Annual Scientific Meeting of the American Headache Society
- 27 Jan 2020 Results published in the Headache
- 12 Nov 2019 According to a Satsuma Pharmaceuticals media release, results from this study were presented at the 19th Congress of the International Headache Society.